Aytu BioPharma Q2 revenue beats expectations

Aytu Biopharma

03/02/2026 21:21

Overview

Pharmaceutical company's Q2 revenue beat analyst expectations

Adjusted EBITDA for Q2 beat analyst expectations

Outlook

Company did not provide specific financial guidance for future quarters or full year in press release

Result Drivers

SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA

INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$15.17 mln
$12.17 mln (3 Analysts)
Q2 Net Income
-$10.58 mln
Q2 Adjusted EBITDA
Beat
-$800,000
-$4.30 mln (3 Analysts)
Q2 Gross Profit
$9.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71

Press Release: ID:nACStMvP3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)